Renin-Angiotensin-Aldosterone System Blockade in Diabetes: Role of Direct Renin Inhibitors

References

• . Wild S, Roglic G, Green A, Sicree R, King H. Global prevalence of diabetes: estimates for the year 2000 and projections for 2030. Diabetes Care. 2004;27(5):1047–1053
   PubMed Web of Science ®Google Scholar
• . American Heart Association. Heart Disease and Stroke Statistics −2008 update. http://www.americanheart.org/downloadable/heart/.1200082005246HS_Stats%202008.final.pdf. Accessed April 11, 2008
   Google Scholar
• . Harris MI. Noninsulin-dependent diabetes mellitus in black and white Americans. Diabetes Metab Rev. 1990;6(2):71–90
   PubMed Web of Science ®Google Scholar
• . Carter JS, Pugh JA, Monterrosa A. Non-insulin-dependent diabetes mellitus in minorities in the United States. Ann Intern Med. 1996;125(3):221–232
   PubMed Web of Science ®Google Scholar
• . Mokdad AH, Ford ES, Bowman BA, . Prevalence of obesity, diabetes, and obesity-related health risk factors, 2001. JAMA. 2003;289(1):76–79
   PubMed Web of Science ®Google Scholar
• . American Diabetes Association. Economic costs of diabetes in the US in 2007. Diabetes Care. 2008;31(3):596–615
   PubMed Web of Science ®Google Scholar
• . Kannel WB, McGee DL. Diabetes and glucose tolerance as risk factors for cardiovascular disease: the Framingham study. Diabetes Care. 1979;2(2):120–126
   PubMedGoogle Scholar
• . Krolewski AS, Kosinski EJ, Warram JH, . Magnitude and determinants of coronary artery disease in juvenile-onset, insulin-dependent diabetes mellitus. Am J Cardiol. 1987;59(8):750–755
   PubMedGoogle Scholar
• . Pyörälä K. Diabetes and heart disease. In: Mogensen CE, Standl E, eds. Prevention and Treatment of Diabetic Late Complications. New York, NY: Walter de Gruyter; 1989:151–168
   Google Scholar
• . Fuller JH, Stevens LK. Epidemiology of hypertension in diabetic patients and implications for treatment. Diabetes Care. 1991;14( suppl 4):8–12
   PubMedGoogle Scholar
• . Satterfield S, Cutler JA, Langford HG, . Trials of hypertension prevention. Phase I design. Ann Epidemiol. 1991;1(5):455–471
   PubMedGoogle Scholar
• . Walker WG, Hermann J, Murphy R, Patz A. Elevated blood pressure and angiotensin II are associated with accelerated loss of renal function in diabetic nephropathy. Trans Am Clin Climatol Assoc. 1986;97:94–104
   PubMedGoogle Scholar
• . Christensen CK, Mogensen CE. The course of incipient diabetic nephropathy: studies of albumin excretion and blood pressure. Diabet Med. 1985;2(2):97–102
   PubMedGoogle Scholar
• . Parving HH, Andersen AR, Smidt UM, Oxenbøll B, Edsberg B, Christiansen JS. Diabetic nephropathy and arterial hypertension. Diabetologia. 1983;24(1):10–12
   PubMedGoogle Scholar
• . Christlieb AR, Warram JH, Królewski AS, . Hypertension: the major risk factor in juvenile-onset insulin-dependent diabetics. Diabetes. 1981;30( suppl 2):90–96
   PubMed Web of Science ®Google Scholar
• . Savage S, Schrier RW. Progressive renal insufficiency: the role of angiotensin converting enzyme inhibitors. Adv Intern Med. 1992;37:85–101
   PubMedGoogle Scholar
• . Knowler WC, Bennett PH, Ballintine EJ. Increased incidence of retinopathy in diabetics with elevated blood pressure. A six-year follow-up study in Pima Indians. N Engl J Med. 1980;302(12):645–650
   PubMed Web of Science ®Google Scholar
• . Ishihara M, Yukimura Y, Aizawa T, Yamada T, Ohto K, Yoshizawa K. High blood pressure as risk factor in diabetic retinopathy development in NIDDM patients. Diabetes Care. 1987;10(1):20–25
   PubMedGoogle Scholar
• . Klein R, Klein BE, Moss SE, Davis MD, DeMets DL. Is blood pressure a predictor of the incidence or progression of diabetic retinopathy? Arch Intern Med. 1989;149(11):2427–2432
   PubMedGoogle Scholar
• . Maser RE, Steenkiste AR, Dorman JS, . Epidemiological correlates of diabetic neuropathy. Report from Pittsburgh Epidemiology of Diabetes Complications Study. Diabetes. 1989;38(11):1456–1461
   PubMed Web of Science ®Google Scholar
• . Dupree EA, Meyer MB. Role of risk factors in complications of diabetes mellitus. Am J Epidemiol. 1980;112(1):100–112
   PubMedGoogle Scholar
• . Nelson RG, Newman JM, Knowler WC, . Incidence of end-stage renal disease in type 2 (non-insulin-dependent) diabetes mellitus in Pima Indians. Diabetologia. 1988;31(10):730–736
   PubMedGoogle Scholar
• . Ferrario CM. Role of angiotensin II in cardiovascular disease: therapeutic implications of more than a century of research. J Renin Angiotensin Aldosterone Syst. 2006;7(1):3–14
   PubMed Web of Science ®Google Scholar
• . Brewster UC, Setaro JF, Perazella MA. The renin-angiotensin-aldosterone system: cardiorenal effects and implications for renal and cardiovascular disease states. Am J Med Sci. 2003;326(1):15–24
   PubMed Web of Science ®Google Scholar
• . Cooper ME. The role of the renin-angiotensin-aldosterone system in diabetes and its vascular complications. Am J Hypertens. 2004;17(11 pt 2):16S–20S
   PubMedGoogle Scholar
• . Touyz RM. Molecular and cellular mechanisms in vascular injury in hypertension: role of angiotensin II. Curr Opin Nephrol Hypertens. 2005;14(2):125–131
   PubMedGoogle Scholar
• . Siragy HM, Carey RM. Protective role of the angiotensin AT2 receptor in a renal wrap hypertension model. Hypertension. 1999;33(5):1237–1242
   PubMedGoogle Scholar
• . Yamada T, Akishita M, Pollman MJ, Gibbons GH, Dzau VJ, Horiuchi M. Angiotensin II type 2 receptor mediates vascular smooth muscle cell apoptosis and antagonizes angiotensin II type 1 receptor action: an in vitro gene transfer study. Life Sci. 1998;63(19):PL289–PL295
   PubMedGoogle Scholar
• . Tone A, Shikata K, Ogawa D, . Changes of gene expression profiles in macrophages stimulated by angiotensin II–angiotensin II induces MCP-2 through AT1-receptor. J Renin Angiotensin Aldosterone Syst. 2007;8(1):45–50
   PubMedGoogle Scholar
• . D'Amore A, Black MJ, Thomas WG. The angiotensin II type 2 receptor causes constitutive growth of cardiomyocytes and does not antagonize angiotensin II type 1 receptor-mediated hypertrophy. Hypertension. 2005;46(6):1347–1354
   PubMedGoogle Scholar
• . Reudelhuber TL. The continuing saga of the AT2 receptor: a case of the good, the bad, and the innocuous. Hypertension. 2005;46(6):1261–1262
   PubMedGoogle Scholar
• . Yan X, Schuldt AJ, Price RL, . Pressure overload-induced hypertrophy in transgenic mice selectively overexpressing AT2 receptors in ventricular myocytes. Am J Physiol Heart Circ Physiol. 2008;294(3):H1274–H1281
   PubMedGoogle Scholar
• . Carey RM, Siragy HM. Newly recognized components of the renin-angiotensin system: potential roles in cardiovascular and renal regulation. Endocr Rev. 2003;24(3):261–271
   PubMed Web of Science ®Google Scholar
• . Hilgers KF, Mann JF. ACE inhibitors versus AT(1) receptor antagonists in patients with chronic renal disease. J Am Soc Nephrol. 2002;13(4):1100–1108
   PubMedGoogle Scholar
• . Chobanian AV, Bakris GL, Black HR, ; National Heart, Lung, and Blood Institute Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure; National High Blood Pressure Education Program Coordinating Committee. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report. JAMA. 2003; 289(19):2560–2572
   PubMed Web of Science ®Google Scholar
• . Riley D, Lang AE, Blair RD, Birnbaum A, Reid B. Frozen shoulder and other shoulder disturbances in Parkinson's disease. J Neurol Neurosurg Psychiatry. 1989;52(1):63–66
   PubMedGoogle Scholar
• . Hunt SA, Baker DW, Chin MH, ; American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee to Revise the 1995 Guidelines for the Evaluation and Management of Heart Failure); International Society for Heart and Lung Transplantation; Heart Failure Society of America. ACC/AHA Guidelines for the Evaluation and Management of Chronic Heart Failure in the Adult: Executive Summary A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee to Revise the 1995 Guidelines for the Evaluation and Management of Heart Failure): Developed in Collaboration With the International Society for Heart and Lung Transplantation; Endorsed by the Heart Failure Society of America. Circulation. 2001; 104(24):2996–3007
   PubMed Web of Science ®Google Scholar
• . United States Renal Data System. 2007 USRDS Annual Data Report: Chronic Kidney Disease. Bethesda, MD: United States Renal Data System; 2007:64–80
   Google Scholar
• . Striker GE, Agodoa LL, Held P, Doi T, Conti F, Striker LJ. Kidney disease of diabetes mellitus (diabetic nephropathy): perspectives in the United States. J Diabet Complications. 1991;5(2–3):51–52
   PubMedGoogle Scholar
• . Nelson RG, Bennett PH, Beck GJ, . Development and progression of renal disease in Pima Indians with non-insulin-dependent diabetes mellitus: Diabetic Renal Disease Study Group. N Engl J Med. 1996;335(22):1636–1642
   PubMedGoogle Scholar
• . Gross JL, de Azevedo MJ, Silveiro SP, Canani LH, Caramori ML, Zelmanovitz T. Diabetic nephropathy: diagnosis, prevention, and treatment. Diabetes Care. 2005;28(1):164–176
   PubMed Web of Science ®Google Scholar
• . Mogensen CE. Microalbuminuria predicts clinical proteinuria and early mortality in maturity-onset diabetes. N Engl J Med. 1984;310(6):356–360
   PubMed Web of Science ®Google Scholar
• . Mann JF, Gerstein HC, Pogue J, Bosch J, Yusuf S. Renal insufficiency as a predictor of cardiovascular outcomes and the impact of ramipril: the HOPE randomized trial. Ann Intern Med. 2001;134(8):629–636
   PubMed Web of Science ®Google Scholar
• . Adler AI, Stevens RJ, Manley SE, Bilous RW, Cull CA, Holman RR. Development and progression of nephropathy in type 2 diabetes: the United Kingdom Prospective Diabetes Study (UKPDS 64). Kidney Int. 2003;63(1):225–232
   PubMed Web of Science ®Google Scholar
• . Wolf G, Ziyadeh FN. The role of angiotensin II in diabetic nephropathy: emphasis on nonhemodynamic mechanisms. Am J Kidney Dis. 1997;29(1):153–163
   PubMed Web of Science ®Google Scholar
• . Leehey DJ, Singh AK, Alavi N, Singh R. Role of angiotensin II in diabetic nephropathy. Kidney Int Suppl. 2000;77:S93–S98
   PubMed Web of Science ®Google Scholar
• . Rosenberg ME, Smith LJ, Correa-Rotter R, Hostetter TH. The paradox of the renin-angiotensin system in chronic renal disease. Kidney Int. 1994;45(2):403–410
   PubMedGoogle Scholar
• . Wolf G. Angiotensin II is involved in the progression of renal disease: importance of non-hemodynamic mechanisms. Nephrologie. 1998;19(7):451–456
   PubMedGoogle Scholar
• . Lewis EJ, Hunsicker LG, Bain RP, Rohde RD. The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. The Collaborative Study Group. N Engl J Med. 1993;329(20):1456–1462
   PubMed Web of Science ®Google Scholar
• . Taguma Y, Kitamoto Y, Futaki G, . Effect of captopril on heavy proteinuria in azotemic diabetics. N Engl J Med. 1985;313(26):1617–1620
   PubMed Web of Science ®Google Scholar
• . Björck S, Mulec H, Johnsen SA, Nordén G, Aurell M. Renal protective effect of enalapril in diabetic nephropathy. BMJ. 1992;304(6823):339–343
   PubMedGoogle Scholar
• . Viberti G, Mogensen CE, Groop LC, Pauls JF. Effect of captopril on progression to clinical proteinuria in patients with insulin-dependent diabetes mellitus and microalbuminuria: European Microalbuminuria Captopril Study Group. JAMA. 1994;271(4):275–279
   PubMedGoogle Scholar
• . Brenner BM, Cooper ME, de Zeeuw D, ; RENAAL Study Investigators. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med. 2001; 345(12):861–869
   PubMed Web of Science ®Google Scholar
• . Lewis EJ, Hunsicker LG, Clarke WR, ; Collaborative Study Group. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med. 2001; 345(12):851–860
   PubMed Web of Science ®Google Scholar
• . Barnett AH, Bain SC, Bouter P, ; Diabetics Exposed to Telmisartan and Enalapril Study Group. Angiotensin-receptor blockade versus converting-enzyme inhibition in type 2 diabetes and nephropathy. N Engl J Med. 2004; 351(19):1952–1961
   PubMed Web of Science ®Google Scholar
• . Casas JP, Chua W, Loukogeorgakis S, . Effect of inhibitors of the renin-angiotensin system and other antihypertensive drugs on renal outcomes: systematic review and meta-analysis. Lancet. 2005;366(9502):2026–2033
   PubMed Web of Science ®Google Scholar
• . Kunz R, Friedrich C, Wolbers M, Mann JF. Meta-analysis: effect of monotherapy and combination therapy with inhibitors of the renin angiotensin system on proteinuria in renal disease. Ann Intern Med. 2008;148(1):30–48
   PubMed Web of Science ®Google Scholar
• . Mogensen CE, Neldam S, Tikkanen I, . Randomised controlled trial of dual blockade of renin-angiotensin system in patients with hypertension, microalbuminuria, and non-insulin dependent diabetes: the candesartan and lisinopril microalbuminuria (CALM) study. BMJ. 2000;321(7274):1440–1444
   PubMed Web of Science ®Google Scholar
• . Rossing K, Jacobsen P, Pietraszek L, Parving HH. Renoprotective effects of adding angiotensin II receptor blocker to maximal recommended doses of ACE inhibitor in diabetic nephropathy: a randomized double-blind crossover trial. Diabetes Care. 2003;26(8):2268–2274
   PubMed Web of Science ®Google Scholar
• . Jacobsen P, Andersen S, Rossing K, Hansen BV, Parving HH. Dual blockade of the renin-angiotensin system in type 1 patients with diabetic nephropathy. Nephrol Dial Transplant. 2002;17(6):1019–1024
   PubMedGoogle Scholar
• . Jacobsen P, Andersen S, Rossing K, Jensen BR, Parving HH. Dual blockade of the renin-angiotensin system versus maximal recommended dose of ACE inhibition in diabetic nephropathy. Kidney Int. 2003;63(5):1874–1880
   PubMed Web of Science ®Google Scholar
• . Tütüncü NB, Gürlek A, Gedik O. Efficacy of ACE inhibitors and ATII receptor blockers in patients with microalbuminuria: a prospective study. Acta Diabetol. 2001;38(4):157–161
   PubMedGoogle Scholar
• . Andersen NH, Poulsen PL, Knudsen ST, . Long-term dual blockade with candesartan and lisinopril in hypertensive patients with diabetes: the CALM II study. Diabetes Care. 2005;28(2):273–277
   PubMed Web of Science ®Google Scholar
• . van den Meiracker AH, Man in 't Veld AJ, Admiraal PJ, . Partial escape of angiotensin converting enzyme (ACE) inhibition during prolonged ACE inhibitor treatment: does it exist and does it affect the antihypertensive response? J Hypertens. 1992;10(8):803–812
   PubMedGoogle Scholar
• . The ONTARGET Investigators; Yusuf S, Teo KK, Pogue J, . Telmisartan, ramipril, or both in patients at high risk for vascular events. N Engl J Med. 2008;358(15):1547–1559
   PubMed Web of Science ®Google Scholar
• . Mann JF, Schmieder RE, McQueen M, ; ONTARGET investigators. Renal outcomes with telmisartan, ramipril, or both, in people at high vascular risk (the ONTARGET study): a multicentre, randomised, double-blind, controlled trial. Lancet. 2008; 372(9638):547–553
   PubMed Web of Science ®Google Scholar
• . Andersen NH, Poulsen PL, Knudsen ST, . Long-term dual blockade with candesartan and lisinopril in hypertensive patients with diabetes: the CALM II study. Diabetes Care. 2005;28(2):273–277
   PubMed Web of Science ®Google Scholar
• . Jacobsen P, Andersen S, Rossing K, Hansen BV, Parving HH. Dual blockade of the renin-angiotensin system in type 1 patients with diabetic nephropathy. Nephrol Dial Transplant. 2002;17(6):1019–1024
   PubMedGoogle Scholar
• . Jacobsen P, Andersen S, Rossing K, Jensen BR, Parving HH. Dual blockade of the renin-angiotensin system versus maximal recommended dose of ACE inhibition in diabetic nephropathy. Kidney Int. 2003;63(5):1874–1880
   PubMed Web of Science ®Google Scholar
• . Palmer BF. Managing hyperkalemia caused by inhibitors of the renin-angiotensin-aldosterone system. N Engl J Med. 2004;351(6):585–592
   PubMed Web of Science ®Google Scholar
• . Bakris GL, Williams M, Dworkin L, . Preserving renal function in adults with hypertension and diabetes: a consensus approach. National Kidney Foundation Hypertension and Diabetes Executive Committees Working Group. Am J Kidney Dis. 2000;36(3):646–661
   PubMed Web of Science ®Google Scholar
• . US National Institutes of Health. VA NEPHRON-D study (CSP#565). www.clinicaltrials.gov/ct2/show/NCT00555217. Accessed May 7, 2008
   Google Scholar
• . Haffner SM, Lehto S, Rönnemaa T, Pyörälä K, Laakso M. Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction. N Engl J Med. 1998;339(4):229–234
   PubMed Web of Science ®Google Scholar
• . Bell DS. Heart failure: the frequent, forgotten, and often fatal complication of diabetes. Diabetes Care. 2003;26(8):2433–2441
   PubMed Web of Science ®Google Scholar
• . Zuanetti G, Latini R, Maggioni AP, Franzosi M, Santoro L, Tognoni G. Effect of the ACE inhibitor lisinopril on mortality in diabetic patients with acute myocardial infarction: data from the GISSI-3 study. Circulation. 1997;96(12):4239–4245
   PubMed Web of Science ®Google Scholar
• . Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO-HOPE substudy. Heart Outcomes Prevention Evaluation Study Investigators. Lancet. 2000;355(9200):253–259
   PubMed Web of Science ®Google Scholar
• . Lindholm LH, Ibsen H, Dahlöf B, ; LIFE Study Group. Cardiovascular morbidity and mortality in patients with diabetes in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet. 2002; 359(9311):1004–1010
   PubMed Web of Science ®Google Scholar
• . Pourdjabbar A, Lapointe N, Rouleau JL. Angiotensin receptor blockers: powerful evidence with cardiovascular outcomes? Can J Cardiol. 2002;18( suppl A):7A–14A
   PubMedGoogle Scholar
• . de Zeeuw D, Remuzzi G, Parving HH, . Albuminuria, a therapeutic target for cardiovascular protection in type 2 diabetic patients with nephropathy. Circulation. 2004;110(8):921–927
   PubMed Web of Science ®Google Scholar
• . Deinum J, Rønn B, Mathiesen E, Derkx FH, Hop WC, Schalekamp MA. Increase in serum prorenin precedes onset of microalbuminuria in patients with insulin-dependent diabetes mellitus. Diabetologia. 1999;42(8):1006–1010
   PubMed Web of Science ®Google Scholar
• . Luetscher JA, Kraemer FB, Wilson DM, Schwartz HC, Bryer-Ash M. Increased plasma inactive renin in diabetes mellitus. A marker of microvascular complications. N Engl J Med. 1985;312(22):1412–1417
   PubMed Web of Science ®Google Scholar
• . Packer M, Poole-Wilson PA, Armstrong PW, . Comparative effects of low and high doses of the angiotensin-converting enzyme inhibitor, lisinopril, on morbidity and mortality in chronic heart failure. ATLAS Study Group. Circulation. 1999;100(23):2312–2318
   PubMed Web of Science ®Google Scholar
• . ONTARGET Investigators; Yusuf S, Teo KK, Pogue J, . Telmisartan, ramipril, or both in patients at high risk for vascular events. N Engl J Med. 2008;358(15):1547–1559
   PubMed Web of Science ®Google Scholar
• . Allan DR, Hui KY, Coletti C, Hollenberg NK. Renin vs angiotensin-converting enzyme inhibition in the rat: consequences for plasma and renal tissue angiotensin. J Pharmacol Exp Ther. 1997;283(2):661–665
   PubMedGoogle Scholar
• . Nguyen G, Delarue F, Burckle C, Bouzhir L, Giller T, Sraer JD. Pivotal role of the renin/prorenin receptor in angiotensin II production and cellular responses to renin. J Clin Invest. 2002;109(11):1417–1427
   PubMed Web of Science ®Google Scholar
• . Nguyen G, Danser AH. Prorenin and (pro)renin receptor: a review of available data from in vitro studies and experimental models in rodents. Exp Physiol. 2008:93(5):557–563
   PubMedGoogle Scholar
• . Danser AH, Deinum J. Renin, prorenin and the putative (pro)renin receptor. Hypertension. 2005;46(5):1069–1076
   PubMed Web of Science ®Google Scholar
• . Danser AH. Novel drugs targeting hypertension: renin inhibitors. J Cardiovasc Pharmacol. 2007;50(2):105–111
   PubMedGoogle Scholar
• . Danser AH, van den Dorpel MA, Deinum J, . Renin, prorenin, and immunoreactive renin in vitreous fluid from eyes with and without diabetic retinopathy. J Clin Endocrinol Metab. 1989;68(1):160–167
   PubMed Web of Science ®Google Scholar
• . Ichihara A, Hayashi M, Kaneshiro Y, . Inhibition of diabetic nephropathy by a decoy peptide corresponding to the “handle” region for nonproteolytic activation of prorenin. J Clin Invest. 2004;114(8):1128–1135
   PubMed Web of Science ®Google Scholar
• . Eder J, Hommel U, Cumin F, Martoglio B, Gerhartz B. Aspartic proteases in drug discovery. Curr Pharm Des. 2007;13(3):271–285
   PubMedGoogle Scholar
• . Nussberger J, Wuerzner G, Jensen C, Brunner HR. Angiotensin II suppression in humans by the orally active renin inhibitor Aliskiren (SPP100): comparison with enalapril. Hypertension. 2002;39(1):E1–E8
   PubMed Web of Science ®Google Scholar
• . Tekturna [package insert]. East Hanover, NJ: Novartis Pharmaceuticals Corp; March 2007
   Google Scholar
• . Tekturna HCT [package insert]. East Hanover, NJ: Novartis Pharmaceutical Corp; January 2008
   Google Scholar
• . Vaidyanathan S, Valencia J, Kemp C, . Lack of pharmacokinetic interactions of aliskiren, a novel direct renin inhibitor for the treatment of hypertension, with the antihypertensives amlodipine, valsartan, hydrochlorothiazide (HCTZ) and ramipril in healthy volunteers. Int J Clin Pract. 2006;60(11):1343–1356
   PubMedGoogle Scholar
• . Waldmeier F, Glaenzel U, Wirz B, . Absorption, distribution, metabolism, and elimination of the direct renin inhibitor aliskiren in healthy volunteers. Drug Metab Dispos. 2007;35(8):1418–1428
   PubMed Web of Science ®Google Scholar
• . Zhao C, Vaidyanathan S, Yeh CM, Maboudian M, Armin Dieterich H. Aliskiren exhibits similar pharmacokinetics in healthy volunteers and patients with type 2 diabetes mellitus. Clin Pharmacokinet. 2006;45(11):1125–1134
   PubMed Web of Science ®Google Scholar
• . Vaidyanathan S, Bigler H, Yeh C, . Pharmacokinetics of the oral direct renin inhibitor aliskiren alone and in combination with irbesartan in renal impairment. Clin Pharmacokinet. 2007;46(8):661–675
   PubMedGoogle Scholar
• . Vaidyanathan S, Warren V, Yeh C, Bizot MN, Dieterich HA, Dole WP. Pharmacokinetics, safety, and tolerability of the oral renin inhibitor aliskiren in patients with hepatic impairment. J Clin Pharmacol. 2007;47(2):192–200
   PubMed Web of Science ®Google Scholar
• . Vaidyanathan S. Lack of pharmacokinetic interaction with the direct renin inhibitor aliskiren with metformin, pioglitazone, and fenofibrate in healthy subjects. Curr Med Res Opin. In press
   Google Scholar
• . Dieterle W, Corynen S, Mann J. Effect of the oral renin inhibitor aliskiren on the pharmacokinetics and pharmacodynamics of a single dose of warfarin in healthy subjects. Br J Clin Pharmacol. 2004;58(4):433–436
   PubMed Web of Science ®Google Scholar
• . Dieterle W, Corynen S, Vaidyanathan S, Mann J. Pharmacokinetic interactions of the oral renin inhibitor aliskiren with lovastatin, atenolol, celecoxib and cimetidine. Int J Clin Pharmacol Ther. 2005;43(11):527–535
   PubMed Web of Science ®Google Scholar
• . Castells L, Vargas V, Allende H, . Combined treatment with pegylated interferon (alpha-2b) and ribavirin in the acute phase of hepatitis C virus recurrence after liver transplantation. J Hepatol. 2005;43(1):53–59
   PubMed Web of Science ®Google Scholar
• . Oparil S, Yarows SA, Patel S, Fang H, Zhang J, Satlin A. Efficacy and safety of combined use of aliskiren and valsartan in patients with hypertension: a randomised, double-blind trial. Lancet. 2007;370(9583):221–229
   PubMed Web of Science ®Google Scholar
• . Uresin Y, Taylor AA, Kilo C, . Efficacy and safety of the direct renin inhibitor aliskiren and ramipril alone or in combination in patients with diabetes and hypertension. J Renin Angiotensin Aldosterone Syst. 2007;8(4):190–198
   PubMed Web of Science ®Google Scholar
• . Villamil A, Chrysant SG, Calhoun D, . Renin inhibition with aliskiren provides additive antihypertensive efficacy when used in combination with hydrochlorothiazide. J Hypertens. 2007;25(1):217–226
   PubMed Web of Science ®Google Scholar
• . American Diabetes Association. Standards of medical care in diabetes−2008. Diabetes Care. 2008;31( suppl 1):S12–S54
   PubMed Web of Science ®Google Scholar
• . Pilz B, Shagdarsuren E, Wellner M, . Aliskiren, a human renin inhibitor, ameliorates cardiac and renal damage in double-transgenic rats. Hypertension. 2005;46(3):569–576
   PubMed Web of Science ®Google Scholar
• . Feldman DL, Jin L, Xuan H, . Effects of aliskiren on blood pressure, albuminuria, and (pro)renin receptor expression in diabetic TG(mRen-2)27 rats. Hypertension. 2008;52(1):130–136
   PubMed Web of Science ®Google Scholar
• . Persson F, Rossing P, Schjoedt KJ, . Time course of the antiproteinuric and antihypertensive effects of direct renin inhibition in type 2 diabetes. Kidney Int. 2008;73(12):1419–1425
   PubMed Web of Science ®Google Scholar
• . Persson FP, Rossing H, Reinhard T, . Renoprotective effects of direct renin inhibition compared to and in combination with irbesartan in patients with type 2 diabetes, hypertension, and albuminuria. Diabetologia. 2008;51( suppl 1):S492
   Google Scholar
• . Parving HH, Persson F, Lewis JB, Lewis EJ, Hollenberg NK; AVOID Study Investigators. Aliskiren combined with losartan in type 2 diabetes and nephropathy. N Engl J Med. 2008; 358(23):2433–2446
   PubMed Web of Science ®Google Scholar
• . Parving HH, Brenner BM, McMurray JJV, . Aliskiren Trial in Type 2 Diabetes Using Cardio-Renal Disease Endpoints (ALTITUDE): rationale and study design. Paper presented at: American Society of Nephrology Renal Week 2007; October 31 to November 5, 2007; San Francisco, CA. Abstract PUB557
   Google Scholar
• . US National Institutes of Health. Aliskiren Trial in Type 2 Diabetes Using Cardiovascular and Renal Disease Endpoints (ALTITUDE). www.clinicaltrials.gov/ct2/show/NCT00549757. Accessed May 7, 2008
   Google Scholar
• . O'Brien E, Barton J, Nussberger J, . Aliskiren reduces blood pressure and suppresses plasma renin activity in combination with a thiazide diuretic, an angiotensin-converting enzyme inhibitor, or an angiotensin receptor blocker. Hypertension. 2007;49(2):276–284
   PubMed Web of Science ®Google Scholar
• . Yarows SA, Oparil S, Patel S, Fang H, Zhang J. Aliskiren and valsartan in stage 2 hypertension: subgroup analysis of a randomized, double-blind study. Adv Ther. 2008;25(12):1288–1302
   PubMedGoogle Scholar
• . Chrysant SG, Murray AV, Hoppe UC, . Long-term safety, tolerability and efficacy of aliskiren in combination with valsartan in patients with hypertension: a 6-month interim analysis. Curr Med Res Opin. 2008;24(4):1039–1047
   PubMed Web of Science ®Google Scholar